SYRS Oct 2024 7.500 call

OPR - OPR Delayed Price. Currency in USD

Add to watchlist

0.8500

0.0000

(0.00%)

As of 12:59PM EDT. Market open.

Simply Wall St.
Syros Pharmaceuticals, Inc.'s (NASDAQ:SYRS) high institutional ownership speaks for itself as stock continues to impress, up 17% over last week
Key Insights Significantly high institutional ownership implies Syros Pharmaceuticals' stock price is sensitive to...
Business Wire
Syros to Host Webcast Event on Higher-Risk Myelodysplastic Syndrome and the Opportunity for Tamibarotene to Become the New Frontline Standard-of-Care for Patients with RARA Gene Overexpression
CAMBRIDGE, Mass., June 13, 2024--Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will host a webcast event with medical experts to discuss the unmet need in higher-risk myelodysplastic syndrome (HR-MDS) and the opportunity for tamibarotene to transform the care of newly diagnosed patients with RARA gene overexpression. The event will take place on Tuesday
GuruFocus.com
Syros Pharmaceuticals Inc (SYRS) (Q1 2024) Earnings Call Transcript Highlights: Strategic ...
Explore key updates on clinical trials, financial shifts, and strategic insights from Syros Pharmaceuticals' Q1 2024 earnings call.